Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia